Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $100.54 USD
Change Today -3.36 / -3.23%
Volume 15.5M
JNJ On Other Exchanges
New York
Sao Paulo
As of 8:04 PM 02/5/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One Johnson & Johnson Plaza

New Brunswick, NJ 08933

United States

Phone: 732-524-0400


Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture and sale of a range of products in the health care field worldwide. The company’s primary focus is products related to human health and well-being. The business of the company is conducted by approximately 265 operating companies located in 60 countries, including the U.S. Segments The company is organized into three segments: Consumer, Pharmaceutical and Medical Devices. Consumer segment The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. Baby Care includes the JOHNSON’S Baby line of products. Oral Care includes the LISTERINE product line. Major brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON’S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Major brands in Women’s Health outside of North America are STAYFREE and CAREFREE sanitary pad and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. The principal nutritional line is SPLENDA No Calorie Sweetener. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. Pharmaceutical segment The Pharmaceutical segment focuses on five therapeutic areas, including immunology (such as rheumatoid arthritis, inflammatory bowel disease, psoriasis and pulmonary diseases), infectious diseases (such as HIV, hepatitis, respiratory infections, tuberculosis and vaccines), neuroscience (such as Alzheimer's disease, mood disorders, schizophrenia and pain), oncology (such as prostate cancer, multiple myeloma, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (such as thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Main products in the Pharmaceutical segment include the following: REMICADE (infliximab), a treatment for immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab) an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO (telaprevir), for the treatment of hepatitis C; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), a treatment for HIV/AIDS; EDURANT (rilpivirine), for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; RISPERDAL CONSTA (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar I Disorder in adults; VELCADE (bortezomib), a treatment for multiple myeloma; ZYTIGA (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; PROCRIT (epoetin alfa, sold outside the U.S. as EPREX), to stimulate red blood cell production; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which might lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $100.54 USD -3.36

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $28.54 USD -0.64
Nestle SA SFr.73.35 CHF -1.05
Novartis AG SFr.73.90 CHF -0.60
Pfizer Inc $29.03 USD +0.03
Roche Holding AG SFr.252.20 CHF -1.30
View Industry Companies

Industry Analysis


Industry Average

Valuation JNJ Industry Range
Price/Earnings 19.0x
Price/Sales 4.2x
Price/Book 4.0x
Price/Cash Flow 18.7x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JOHNSON & JOHNSON, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at